FRLN
Closed
Freeline Therapeutics holdings Plc
6.48
0.00 (0.00%)
Last Update: 29 Feb 2024 17:30:00
Yesterday: 6.48
Day's Range: 6.48 - 6.48
Send
sign up or login to leave a comment!
When Written:
0.455
Freeline Therapeutics Holdings Plc is a clinical-stage biotechnology company that focuses on developing gene therapies for rare diseases. The company was founded in 2015 and is headquartered in the UK. Freeline's gene therapies are designed to address the underlying genetic cause of the disease by providing a functional copy of the missing or defective gene. The company's lead product candidate, FLT180a, is being developed for the treatment of Hemophilia B. Freeline is also developing gene therapies for Fabry disease and Gaucher disease. The company went public on the NASDAQ in September 2020 and raised $159 million in its initial public offering.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








